Related Experiment Video
Updated: Sep 9, 2025
08:42
Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China
Published on: February 11, 2022
3.6K
Cardioinhibitory reflex syncope : Cardioneuroablation as a therapeutic alternative
Amelie Beblo1, Robert Hättasch2, Nikolaos Dagres2
1Klinik für Kardiologie, Angiologie und Intensivmedizin, Campus Mitte, Deutsches Herzzentrum der Charité, Charitéplatz 1, 10117, Berlin, Germany. amelie.beblo@dhzc-charite.de.
Herzschrittmachertherapie & Elektrophysiologie
|August 28, 2025
Summary
Cardioneuroablation (CNA) effectively treated a young patient with recurrent cardioinhibitory reflex syncope. This minimally invasive procedure offers a safe alternative to pacemakers for select patients.
Area of Science:
- Cardiology
- Electrophysiology
- Neurology
Background:
- Recurrent reflex syncope, particularly cardioinhibitory syncope, significantly impacts quality of life.
- Traditional treatment options for severe cases, such as pacemaker implantation, may not be suitable for all patients, especially younger individuals.
Purpose of the Study:
- To report a case of successful cardioneuroablation (CNA) in a young patient with severe, recurrent cardioinhibitory reflex syncope.
- To evaluate CNA as a safe and effective alternative to pacemaker implantation.
Main Methods:
- A 36-year-old female patient with documented asystolic episodes (up to 9 seconds) underwent cardioneuroablation (CNA).
- An implantable loop recorder was used to confirm the diagnosis and monitor the patient's response.
Main Results:
- Cardioneuroablation (CNA) was performed without complications.
- The patient experienced a significant reduction in syncope episodes, demonstrating the efficacy of CNA.
Conclusions:
- Cardioneuroablation (CNA) is a viable and safe treatment for recurrent cardioinhibitory reflex syncope in young, symptomatic patients.
- CNA should be considered in specialized centers for patients under 40 years old when conservative measures fail.
Related Concept Videos
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
75
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
75
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
845
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
845
01:25Dysrhythmias VI: Management of Dysrhythmias
106
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
106
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
985
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
985
01:26Heart Failure Drugs: Inotropic Agents
717
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
717